Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival

BACKGROUND: Patients treated with immune checkpoint inhibitors (ICIs) may experience pseudoprogression, which can be classified as progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1 and could lead to inappropriate treatment discontinuation. Immune-response criter...

Descripción completa

Detalles Bibliográficos
Autores principales: Manitz, Juliane, D'Angelo, Sandra P, Apolo, Andrea B, Eggleton, S Peter, Bajars, Marcis, Bohnsack, Oliver, Gulley, James L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886415/
https://www.ncbi.nlm.nih.gov/pubmed/35228264
http://dx.doi.org/10.1136/jitc-2021-003302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886415/
https://www.ncbi.nlm.nih.gov/pubmed/35228264
http://dx.doi.org/10.1136/jitc-2021-003302

Ejemplares similares